AMGEN Inc.

NASDAQ:AMGN   3:59:59 PM EDT
251.30
+1.95 (+0.78%)
Products

Amgen Submits Sotorasib New Drug Application To U.S. FDA For Advanced Or Metastatic Non-Small Cell Lung Cancer With Kras G12c Mutation

Published: 12/16/2020 21:45 GMT
AMGEN Inc. (AMGN) - Amgen Submits Sotorasib New Drug Application to U.S. FDA for Advanced Or Metastatic Non-small Cell Lung Cancer With Kras G12c Mutation.
Amgen Inc - FDA Granted Breakthrough Therapy Designation for Sotorasib.
Amgen Inc - Sotorasib Application Being Reviewed Under FDA Real-time Oncology Review (rtor) Pilot Program.